Capital Fund Management S.A. Makes New $1.14 Million Investment in Alkermes plc $ALKS

Capital Fund Management S.A. bought a new stake in Alkermes plc (NASDAQ:ALKS) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 39,929 shares of the company’s stock, valued at approximately $1,142,000.

Other large investors have also modified their holdings of the company. Twin Tree Management LP purchased a new position in Alkermes in the 1st quarter valued at $29,000. Armstrong Advisory Group Inc. purchased a new position in Alkermes during the 2nd quarter worth $29,000. Brooklyn Investment Group lifted its stake in shares of Alkermes by 1,071.1% in the 1st quarter. Brooklyn Investment Group now owns 1,054 shares of the company’s stock worth $35,000 after acquiring an additional 964 shares during the period. Quantbot Technologies LP boosted its holdings in shares of Alkermes by 54.5% in the first quarter. Quantbot Technologies LP now owns 1,091 shares of the company’s stock valued at $36,000 after acquiring an additional 385 shares in the last quarter. Finally, BNP PARIBAS ASSET MANAGEMENT Holding S.A. purchased a new stake in shares of Alkermes in the second quarter valued at about $49,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on the stock. Truist Financial increased their price target on shares of Alkermes from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, November 17th. Wall Street Zen downgraded Alkermes from a “strong-buy” rating to a “buy” rating in a research note on Sunday, November 9th. Royal Bank Of Canada raised their price target on Alkermes from $45.00 to $47.00 and gave the company an “outperform” rating in a report on Wednesday, October 22nd. Deutsche Bank Aktiengesellschaft dropped their price objective on Alkermes from $55.00 to $45.00 and set a “buy” rating on the stock in a report on Thursday, November 13th. Finally, HC Wainwright reissued a “neutral” rating on shares of Alkermes in a report on Wednesday, October 22nd. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $44.69.

Insider Activity at Alkermes

In related news, EVP Craig C. Hopkinson sold 4,000 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $29.30, for a total value of $117,200.00. Following the sale, the executive vice president directly owned 65,740 shares of the company’s stock, valued at approximately $1,926,182. This represents a 5.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have sold 22,000 shares of company stock valued at $674,390. 4.40% of the stock is owned by insiders.

Alkermes Price Performance

ALKS opened at $29.30 on Friday. Alkermes plc has a 1-year low of $25.17 and a 1-year high of $36.45. The stock has a market cap of $4.84 billion, a P/E ratio of 14.51, a P/E/G ratio of 1.42 and a beta of 0.49. The stock’s 50 day simple moving average is $30.42 and its 200 day simple moving average is $29.38.

Alkermes (NASDAQ:ALKS) last issued its quarterly earnings data on Tuesday, October 28th. The company reported $0.49 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.41 by $0.08. The firm had revenue of $394.19 million during the quarter, compared to analysts’ expectations of $355.23 million. Alkermes had a return on equity of 21.81% and a net margin of 22.27%.Alkermes’s revenue was up 4.3% on a year-over-year basis. During the same period in the previous year, the firm posted $0.73 earnings per share. Alkermes has set its FY 2025 guidance at 1.360-1.470 EPS. Research analysts expect that Alkermes plc will post 1.31 EPS for the current fiscal year.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.